Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients

J Río, À Rovira, C Gasperini, M Tintoré, L Prosperini, S Otero-Romero, M Comabella, Á Vidal-Jordana, I Galán, L Midaglia, B Rodriguez-Acevedo, A Zabalza, J Castilló, G Arrambide, C Nos, Á Cobo-Calvo, C Tur, C Auger, J Sastre-Garriga, X Montalban

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

11 Cites (Scopus)

Resum

Background and objectives
Different treatment response scoring systems in treated MS patients exist. The objective was to assess the long-term predictive value of these systems in RRMS patients treated with self-injectable DMTs.

Methods
RRMS-treated patients underwent brain MRI before the onset of therapy and 12 months thereafter, and neurological assessments every 6 months. Clinical and demographic characteristics were collected at baseline. After the first year of treatment, several scoring systems [Rio score (RS), modified Rio score (MRS), MAGNIMS score (MS), and ROAD score (RoS)] were calculated. Cox-Regression and survival analyses were performed to identify scores predicting long-term disability.

Results
We included 319 RRMS patients. Survival analyses showed that patients with RS > 1 and RoS > 3 had a significant risk of reaching an EDSS of 4.0 and 6.0 The score with the best sensitivity (61%) was the RoS, while the MRS showed the best specificity (88%). The RS showed the best positive predictive value (42%) and the best accuracy (81%).

Conclusions
The combined measures integrated into different scores have an acceptable prognostic value for identifying patients with long-term disability.

Thus, these data reinforce the concept of early treatment optimization to minimize the risk of long-term disability.
Idioma originalAnglès
Pàgines (de-a)452-459
Nombre de pàgines8
RevistaJournal of Neurology
Volum269
Número1
DOIs
Estat de la publicacióPublicada - de gen. 2022

Fingerprint

Navegar pels temes de recerca de 'Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients'. Junts formen un fingerprint únic.

Com citar-ho